Current and Future Therapeutic Approaches to the Fentanyl Crisis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (5 March 2024) | Viewed by 145
Special Issue Editor
2. Department of Pharmacology, and Functional Electrical Stimulation Center, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
Interests: opioids; brain systems; autonomic physiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The opioid epidemic driven by fentanyl is a clear and present danger to our society. Fentanyl in itself and when purposefully or accidentally taken with other drugs such as cocaine, heroin and methamphetamine (there is growing instances of these drugs being laced with fentanyl) leads to deaths via opioid-induced respiratory depression (OIRD) and also to addiction and physical dependence. Current medical assistance treatment (MAT) programs developed to treat heroin use disorder, such as those incorporating buprenorphine, are not proving successful for fentanyl use disorder. Moreover, opioid receptor antagonists are proving less than efficacious in attempting to reverse OIRD caused by fentanyl and especially fentanyl in combination with other drugs that disturb respiratory function such as those mentioned above. This Special Issue “Current and future therapeutic approaches to the fentanyl crisis " seeks inputs (reviews, commentaries, original research articles) from clinicians and scientists on (1) current state of the fentanyl crisis and MAT programs, (2) development of novel approaches and therapies for fentanyl-induced addiction and dependence and fentanyl-induced OIRD.
Prof. Dr. Stephen J. Lewis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- fentanyl
- opioid use disorder (OUD)
- opioid-induced respiratory depression (OIRD)
- addiction
- dependence
- medical-assistance treatment (MAT)
- substance use disorder (SUD)
- cocaine
- heroin
- methamphetamine
